Compare Allstate Corp (ALL) vs Pfizer Inc (PFE) Price & Performance

Allstate (ALL) trades at $251.61, up 1.19% on the day, with a bullish technical outlook and strong fundamental momentum. The stock shows robust earnings beats in recent quarters, a low P/E of 5.57, and a high ROE of 48.44%. Recent news highlights dividend declarations and anticipation for Q2 2026 earnings, with analysts citing improved underwriting and catastrophe performance as key drivers.

The outlook remains positive given valuation discounts and earnings growth, but risks include hurricane season exposure and competitive pressures. Upside potential is supported by a consensus price target of $251.18, with Wall Street largely holding a buy or neutral stance, though near-term volatility may arise from earnings results due August 6, 2026.

Pfizer (PFE) trades at $24.17, down 0.33% on the day, with a bearish technical signal and neutral oscillators. The company maintains solid fundamentals with a P/E of 18.45, net income margin of 11.83%, and consistent quarterly earnings beats. Recent news highlights pipeline developments in obesity and oncology, with a $0.43 quarterly dividend providing income stability.

The outlook remains mixed: analyst consensus targets $27.63 (14% upside) but technicals suggest near-term pressure. Key risks include patent cliffs and competitive threats, while institutional sentiment leans hold. Valuation appears reasonable relative to cash flow generation, making PFE a defensive play with moderate growth potential amid ongoing pipeline execution.